Financials Jamjoom Pharmaceuticals Factory Company

Equities

4015

SA15QGU1UNH6

Pharmaceuticals

Market Closed - Saudi Arabian S.E. Other stock markets 08:20:05 2024-05-09 am EDT			5-day change	1st Jan Change
140 ^SAR	+1.01%		+5.42%	+21.74%

03:07pm	Tadawul Shares Plunge Thursday as Saudi Arabia’s March Industrial Output Falls	MT
07:39am	Jamjoom Pharmaceuticals Posts Higher Q1 Net Profit, Revenue	MT

Valuation

Fiscal Period: December	2023	2024	2025	2026
Capitalization ¹	8,050	9,702	-	-
Enterprise Value (EV) ¹	7,766	9,396	9,287	9,153
P/E ratio	27.5 x	31.1 x	25.4 x	21.1 x
Yield	0.87%	2.12%	2.42%	2.8%
Capitalization / Revenue	7.31 x	7.61 x	6.66 x	5.81 x
EV / Revenue	7.05 x	7.37 x	6.38 x	5.48 x
EV / EBITDA	22.6 x	24.3 x	20.8 x	17.8 x
EV / FCF	31 x	34.8 x	25.7 x	20.7 x
FCF Yield	3.23%	2.87%	3.89%	4.84%
Price to Book	-	6.5 x	5.86 x	5.31 x
Nbr of stocks (in thousands)	70,000	70,000	-	-
Reference price ²	115.0	138.6	138.6	138.6
Announcement Date	3/25/24	-	-	-

¹SAR in Million²SAR

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2022	2023	2024	2025	2026
Net sales ¹	-	1,101	1,275	1,456	1,669
EBITDA ¹	-	344.3	386.8	446.5	515
EBIT ¹	-	313.4	359.7	416.5	473.5
Operating Margin	-	28.47%	28.21%	28.61%	28.36%
Earnings before Tax (EBT)	-	315.8	-	-	-
Net income ¹	171.3	292.4	312.3	381.5	459.5
Net margin	-	26.56%	24.5%	26.2%	27.53%
EPS ²	2.450	4.180	4.462	5.449	6.564
Free Cash Flow ¹	-	250.9	270	361	443
FCF margin	-	22.79%	21.18%	24.8%	26.54%
FCF Conversion (EBITDA)	-	72.85%	69.8%	80.85%	86.01%
FCF Conversion (Net income)	-	85.79%	86.45%	94.64%	96.42%
Dividend per Share ²	-	1.000	2.935	3.360	3.880
Announcement Date	5/4/23	3/25/24	-	-	-

¹SAR in Million²SAR

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1
Net sales ¹	-	298.4	292.6	207.9	385.5
EBITDA	-	-	-	-	-
EBIT	-	-	-	-	-
Operating Margin	-	-	-	-	-
Earnings before Tax (EBT)	-	-	-	-	-
Net income ¹	84.4	-	-	-	76.5
Net margin	-	-	-	-	27.42%
EPS	1.210	-	-	-	-
Dividend per Share	-	-	-	-	-
Announcement Date	7/2/23	8/15/23	11/8/23	3/25/24	-

¹SAR in Million

Estimates

Balance Sheet Analysis

Fiscal Period: December	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-
Net Cash position ¹	-	284	306	415	549
Leverage (Debt/EBITDA)	-	-	-	-	-
Free Cash Flow ¹	-	251	270	361	443
ROE (net income / shareholders' equity)	-	22.3%	21.8%	22.4%	23.5%
ROA (Net income/ Total Assets)	-	19.1%	19%	19.9%	19.8%
Assets ¹	-	1,531	1,640	1,914	2,318
Book Value Per Share ²	-	-	21.30	23.70	26.10
Cash Flow per Share	-	-	-	-	-
Capex ¹	-	45.2	65	45	43
Capex / Sales	-	4.1%	5.1%	3.09%	2.58%
Announcement Date	5/4/23	3/25/24	-	-	-

¹SAR in Million²SAR

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Jamjoom Pharmaceuticals Factory Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

140 SAR

Average target price

142.1 SAR

Spread / Average Target

+1.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
JAMJOOM PHARMACEUTICALS FACTORY COMPANY	+21.74%	2.59B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+18.67%	43.74B
OTSUKA HOLDINGS CO., LTD.	+21.99%	22.26B
SANDOZ GROUP AG	+16.41%	14.9B
CIPLA LIMITED	+9.03%	13.39B
ZYDUS LIFESCIENCES LIMITED	+40.48%	12.12B
ONO PHARMACEUTICAL CO., LTD.	-9.64%	6.92B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+12.41%	5.47B

Generic Pharmaceuticals